Jamie is a Managing Partner at Frazier Life Sciences and has led many of the firm’s successful investments, including Acerta Pharma BV (sold to AstraZeneca), Amunix Pharmaceuticals (sold to Sanofi), Calistoga Pharmaceuticals (co-founder, sold to Gilead Sciences), Mavupharma (sold to AbbVie), and Portola Pharmaceuticals (co-founder, sold to Alexion). In addition to Phathom, he currently represents Frazier on the boards of Alpine Immune Sciences (NASDAQ: ALPN), AnaptysBio (NASDAQ: ANAB), Enlaza Therapeutics, Lassen Therapeutics, and Seraxis. Jamie also serves as the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC). In addition, he is a board observer for Alcresta Therapeutics.
Prior to joining Frazier, Jamie was the head of cardiovascular R&D at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the medical school faculties at Stanford and Harvard Medical School prior to joining COR.
Jamie received his M.D. and Ph.D. in Biophysics from Stanford and holds a B.S. from the University of Michigan. He did his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women’s Hospital in Boston. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford.
What is James N. Topper's net worth?
The estimated net worth of James N. Topper is at least $44.52 million as of September 15th, 2025. Topper owns 3,028,524 shares of Phathom Pharmaceuticals stock worth more than $44,519,303 as of December 5th. This net worth estimate does not reflect any other assets that Topper may own. Learn More about James N. Topper's net worth.
How do I contact James N. Topper?
Has James N. Topper been buying or selling shares of Phathom Pharmaceuticals?
James N. Topper has not been actively trading shares of Phathom Pharmaceuticals over the course of the past ninety days. Most recently, on Wednesday, May 21st, James N. Topper bought 3,780 shares of Phathom Pharmaceuticals stock. The stock was acquired at an average cost of $3.86 per share, with a total value of $14,590.80. Following the completion of the transaction, the director now directly owns 59,403 shares of the company's stock, valued at $229,295.58. Learn More on James N. Topper's trading history.
Who are Phathom Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Phathom Pharmaceuticals?
During the last year, Phathom Pharmaceuticals insiders bought shares 3 times. They purchased a total of 21,280 shares worth more than $126,715.80. During the last year, insiders at the sold shares 9 times. They sold a total of 42,342 shares worth more than $284,083.77. The most recent insider tranaction occured on November, 3rd when insider Robert Charles Breedlove sold 524 shares worth more than $7,079.24. Insiders at Phathom Pharmaceuticals own 23.0% of the company.
Learn More about insider trades at Phathom Pharmaceuticals. Information on this page was last updated on 11/3/2025.
